TD Cowen Issues Positive Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price objective boosted by equities researchers at TD Cowen from $255.00 to $270.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. TD Cowen’s price target indicates a potential upside of 14.78% from the stock’s previous close.

A number of other equities research analysts have also commented on DHR. Barclays reiterated an “overweight” rating and issued a $260.00 price target on shares of Danaher in a research report on Thursday. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Sunday. Evercore reiterated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a report on Monday, July 6th. Morgan Stanley boosted their price target on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Danaher in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $239.50.

Danaher Price Performance

DHR stock opened at $235.23 on Thursday. The company has a market capitalization of $165.37 billion, a P/E ratio of 41.80, a PEG ratio of 2.82 and a beta of 0.76. The company has a fifty day moving average price of $215.25 and a 200-day moving average price of $196.84. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.89 earnings per share. As a group, equities analysts expect that Danaher will post 8.53 EPS for the current year.

Institutional Trading of Danaher

Several hedge funds have recently modified their holdings of the stock. NBT Bank N.A. bought a new position in Danaher during the third quarter worth $8,559,000. Root Financial Partners LLC raised its holdings in shares of Danaher by 15.6% during the third quarter. Root Financial Partners LLC now owns 1,796 shares of the conglomerate’s stock valued at $398,000 after purchasing an additional 243 shares during the period. Lmcg Investments LLC raised its holdings in shares of Danaher by 1.3% during the third quarter. Lmcg Investments LLC now owns 126,026 shares of the conglomerate’s stock valued at $27,921,000 after purchasing an additional 1,599 shares during the period. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Danaher during the 3rd quarter worth about $997,000. Finally, Canoe Financial LP grew its stake in shares of Danaher by 43.3% in the 3rd quarter. Canoe Financial LP now owns 800,124 shares of the conglomerate’s stock valued at $169,434,000 after buying an additional 241,910 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, well above the $1.92 consensus estimate. Revenue rose 8.3% year over year to $6.55 billion, essentially in line with expectations, while stronger Biotechnology profitability supported margin expansion. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, above the prior outlook and analyst expectations. Biotechnology orders grew at a mid-teens rate, suggesting improving customer demand and a potentially stronger recovery across key end markets. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more constructive following the results. Stifel Nicolaus raised its price target from $220 to $260 and upgraded DHR to Buy, while Robert W. Baird lifted its target from $246 to $254 and assigned an Outperform rating. Goldman Sachs also increased its target to $275 from $250. Goldman Sachs Adjusts Price Target on Danaher
• Positive Sentiment: Management highlighted artificial-intelligence capabilities as a longer-term growth opportunity in drug discovery, while the Masimo acquisition helped offset weakness in respiratory diagnostic sales. Danaher says it has building blocks for AI drug discovery growth

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.